A wireless system to monitor opioid withdrawal in newborns.
Official title: Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.
Funded at Rekovar INC. · NIH-11065556 · Data updated 2026-11-12
This study is testing a new wearable device called Neomonki that helps doctors keep an eye on newborns who are going through withdrawal from opioids, making it easier to provide better care and possibly reduce the need for medication and hospital time.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rekovar INC. NIH-funded |
| Lab location | 1 site (Lake Forest, UNITED STATES) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $317,925 |
| NIH project number | 3R44DA049615-03S2 |
| Project ID | NIH-11065556 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are newborns aged 0-4 weeks who are diagnosed with Neonatal Abstinence Syndrome due to in utero opioid exposure.
✕Less likely to help
Patients who are not newborns or those who do not exhibit symptoms of Neonatal Abstinence Syndrome may not benefit from this research.
What this research studies
This research focuses on developing a wearable monitoring device called Neomonki to help assess and treat Neonatal Abstinence Syndrome (NAS) in newborns exposed to opioids in utero. The device uses biosensor technology to track behavioral and physiological symptoms, providing objective data that can improve diagnosis and treatment decisions. By utilizing a tablet and wireless wristbands, healthcare providers can receive real-time updates on the infant's condition, potentially reducing the need for medication and hospital stays. The goal is to enhance the care of infants in Neonatal Intensive Care Units (NICUs) while minimizing costs and risks associated with current treatment methods.
Why it matters
Potential benefit: If successful, this research could lead to more accurate assessments and better management of Neonatal Abstinence Syndrome, ultimately improving outcomes for affected newborns.
How similar studies have gone: While the approach of using wearable technology for monitoring is gaining traction, this specific application for NAS is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
Rekovar INC.
Lake Forest, United States Active
Researchers
- Principal investigator: Sharareh, Shiva — Rekovar INC.
- Study coordinator: Sharareh, Shiva
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.